ArticlePeerJ2025
Survival prediction in gliomas based on MRI radiomics combined with clinical factors and molecular biomarkers.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Are AI Neuroimaging Models Ready for Clinical Use? A Systematic Methodological Review.Journal of clinical medicine · 2026Review
- Radiomic analysis of the peritumoral zone identifies imaging signatures of glioma invasion associated with HSP70 expression.Frontiers in oncology · 2026Article
- MRI-derived habitat heterogeneity for overall survival risk stratification in IDH-wildtype, CNS WHO grade 4 glioblastoma.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To investigate the practicability of a radiomics signature combined with clinical factors and molecular biomarkers for predicting overall survival (OS) in glioma patients. Methods: Training ( Results: The radiomics signature based on the combined sequences indicated exceptional predictive ability for OS in three cohorts and stratified glioma patients significantly into high-risk and low-risk groups ( Conclusion: The radiomics signature demonstrates superior predictive performance for OS in glioma patients and significant subgroup risk stratification efficiency. Moreover, the comprehensive model combining clinical factors, molecular biomarkers, and radiomics features further achieves a robust assessment of survival prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.